Strong demand for dietary supplements and successful launches of dermatology and pain products helped Bayer Consumer Health to grow faster than the market in 2021. And the company is bullish about repeating this feat in 2022 with sales growth expected to be driven by cough and cold products and the US launch of Astepro Allergy following its switch last year.
Bayer Consumer Health reported Consumer Health sales up by 6.5% – adjusted for currency and portfolio effects – to €5.29bn...








